IL-27beta Polyclonal Antibody, FITC Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-8606R-FITC-100uL |
| Product Name | IL-27beta Polyclonal Antibody, FITC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human EBI3/IL-27beta |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Subcellular location | Cytoplasm, Secreted |
| Synonyms | cytokine receptor; EBI3; EBV induced gene 3 protein; EBV-induced gene 3 protein; Epstein Barr virus induced 3; Epstein Barr virus induced gene 3; Epstein Barr virus induced gene 3 protein; Epstein-Barr virus-induced gene 3 protein; IL 27 subunit beta; IL 27B; IL-27 subunit beta; IL-27B; IL27 subunit; IL27 subunit beta; IL27B; IL27B_HUMAN; IL35 subunit; interleukin 27 subunit beta; Interleukin-27 subunit beta. |
| Background | Epstein-Barr virus-induced gene 3 (Ebi3) is a widely expressed homolog to the interleukin IL-12 p40 subunit protein that forms a heterodimer with either IL-12 p35 or an IL-12 p35 homolog, p28, to create a new cytokine (IL-27). Ebi3 may function to antagonize IL-12 and to inhibit the development of a Th1 immune response. Ebi3 is strongly expressed in Hodgkin and Reed-Sternberg cells, independently of the EBV status of the tumor cells. Ebi2 is expressed in B-lymphocytes and lymphoid tissues and may function in the modulation of the immune system. Out of the nine genes that are induced by the Epstein-Barr virus, Ebi2 exhibits the highest levels of up-regulation. In addition, Ebi2 may play a role mediating normal lymphocyte functions. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is IL-27beta Polyclonal Antibody, FITC Conjugated (bs-8606R-FITC) validated for, and at what dilution?
bs-8606R-FITC is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-8606R-FITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise IL-27beta Polyclonal Antibody, FITC Conjugated (bs-8606R-FITC)?
KLH conjugated synthetic peptide derived from human EBI3/IL-27beta
What are the excitation and emission wavelengths of the FITC conjugate (bs-8606R-FITC)?
FITC on bs-8606R-FITC: excitation / emission 494nm/518nm.